

Special Issue

Liquid Biopsy in Breast Cancer (2nd Edition)

Message from the Guest Editors

We are excited to invite you to contribute to this Special Issue—the second edition of “Liquid Biopsy in Breast Cancer” Liquid biopsy is being increasingly recognized as a valuable non-invasive tool for the management of patients with solid tumors. It mainly includes the analysis of intact circulating tumor cells (CTCs), nucleic acids such as circulating tumor DNA (ctDNA) and circulating miRNAs, as well as exosomes/extracellular vesicles. CTC enumeration emerged as the first liquid biopsy analyte with clinical relevance in breast cancer (BC) in as early as 2004, and, since then, large clinical trials have verified the role of CTCs in the prediction of relapse or disease progression, as well as the survival of metastatic BC patients. This Special Issue of *Cancers* welcomes contributions that present new data and address or discuss liquid biopsy biomarkers with prognostic and/or predictive relevance in BC.

Guest Editors

Dr. Maria Papadaki

Laboratory of Translational Oncology, School of Medicine, University of Crete, Heraklion, Greece

Prof. Dr. Dimitrios Mavroudis

Head, Department of Medical Oncology, University of Crete Medical School, Heraklion, Greece

Deadline for manuscript submissions

closed (31 August 2025)



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/199246

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)